NVAX - ノババックス （Novavax Inc.）

In the last trading session, 3.75 million shares of the Novavax Inc. (NASDAQ:NVAX) were traded, and its beta was 1.85. Most recently the company’s share price was $18.20, and it changed around -$0.37 or -1.99% from the last close, which brings the market valuation of the company to $1.45B. NVAX currently trades at a discount … Novavax Inc. (NASDAQ: NVAX): It Is A Stock Worth Considering Today Read More »

REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS ), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology industry veteran with more than three decades of research and development, operations and commercialization expertise across his time with Takeda Pharmaceutical Co., Novavax, Inc. and Merck & Co., Inc. He currently serves as the Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, which he co-founded and built, with end-to-end manufacturing and digital solutions across several modalities including cell and gene therapies, nucleic acids, vaccines and biologics. "Rahul is a proven leader in the biopharmaceutical industry, with a demonstrated track record of enabling scale and accelerating the growth of innovative product pipelines," said Byron Dorgan, Chair of the Board of Codexis. "His insights and guidance across drug development and driving adoption of boundary-pushing technologies will prove invaluable throughout Codexis'' evolution, and we are fortunate to welcome him to …

Novavax is the hypercoaster of stocks having crested $300 in 02/22, falling to <$130 and then doubling and then crashing. See why NVAX is a tricky holding.

The shares of COVID-19 vaccine makers witnessed a sharp decline on Thursday morning, with Moderna (MRNA) and Novavax (NVAX) reaching 52-week lows.Its rivals in COVID-19 vaccine…

Swiss life sciences company Siegfried Holding AG (SGFEF) announced Wednesday that it decided to extend the collaboration with Novavax (NVAX) for the fill & finish process of the U.S

After various setbacks, Novavax (NVAX) finally managed to get its Covid-19 vaccine across the finish line this year. That has done little, however, to alter the sto…

A syringe is checked prior to a booster vaccine by a Nomi Health worker in West Valley City on July 14, 2022. Jeffrey D. Allred, Deseret News The new omicron-targeted COVID-19 booster shots may be shipping Friday, but aren’t expected to be widely available until after the Labor Day holiday. The first updated COVID-19 booster doses — also known as “bivalent vaccines” — from Pfizer and Moderna won quick approval this week from the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention to be ready for another potential COVID-19 surge this fall. Related Forget herd immunity. Best case may be ‘herd safety,’ new COVID-19 study suggests Here’s what you need to know: Who can get an omicron booster shot? Teens and adults who have been fully vaccinated for at least two months. Fully vaccinated means having received the first two doses of the original Pfizer or Moderna vaccine, or the recently approved Novavax vaccine , or the single dose of the Johnson & Johnson vaccine that’s no longer recommended for most people Teens and adults who have waited at least two months since their most recent booster shot Pfizer’s omicron booster is authorized for people 12 and older Modern’s omicron booster is authorized for people 18 and older Related Will Novavax be the ‘perfect option’ for those still unvaccinated against COVID-19?

GAITHERSBURG, Md., Sept. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious d…

GAITHERSBURG, Md., Sept. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has expanded its temporary authorization of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in Switzerland for

In last trading session, Novavax Inc. (NASDAQ:NVAX) saw 4.73 million shares changing hands with its beta currently measuring 1.48. Company’s recent per share price level of $31.95 trading at -$1.09 or -3.30% at ring of the bell on the day assigns it a market valuation of $2.64B. That closing price of NVAX’s stock is at … Novavax Inc. (NASDAQ:NVAX) Currently -769.48% Below Its 52-Week High, But There May Be A Surprise Downside Read More »

July 02, 2022 9:41 AM It is accelerating development of shots to protect against the BA.4 and BA.5 subvariants.

On Tuesday afternoon, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 19-2 to recommend that…

Novavax Inc. announced on Friday that it expects "to provide an Omicron-containing vaccine" by the last quarter of this year. "Novavax is already well underway in our variant program and will acceler…

Novavax Inc NVAX.O said on Friday it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter.

One of the retail favorites that’s surging in today’s mixed markets is Novavax (NASDAQ: NVAX ). NVAX stock is up around 10% today at the time of writing. That’s good news for investors who have held this stock for some time. After all, Novavax has lost more than 60% of its value year-to-date. And that’s including today’s surge higher. This positive move in NVAX stock appears to be tied to recent reports about the potential for surging Covid-19 cases this winter. Additionally, a company statement regarding the efficacy of Novavax’s Covid-19 vaccines against all variants is something investors are taking positively. It’s important to keep these news items in context. Earlier this month, Novavax received approval from the Food and Drug Administration (FDA) to distribute its vaccine. With a delay in this approval ultimately hitting NVAX stock hard, investors appear to have grown impatient with this stock. After all, the window of opportunity for vaccine makers may be closing, as more of the population is inoculated.